about
Different oral corticosteroid regimens for acute asthmaIntravenous magnesium sulfate for treating children with acute asthma in the emergency departmentRemote versus face-to-face check-ups for asthmaLong-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthmaLong-acting muscarinic antagonists (LAMA) added to combination long-acting beta 2 -agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthmaDifferent oral corticosteroid regimens for acute asthmaLong-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthmaStopping long-acting beta 2 -agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroidsMacrolides for chronic asthmaLong-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta 2 -agonists (LABA) for adults with asthmaLong-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthmaSublingual immunotherapy for asthmaLong-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthmaStopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroidsLong-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthmaRemote versus face-to-face asthma reviewsAsthma monitoring with remote feedback from a health professionalLong-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS for adults with asthmaStopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroidsStopping long-acting beta2-agonists (LABA) for adults with asthma well-controlled on LABA and inhaled corticosteroidsSublingual immunotherapy for asthmaIntravenous magnesium sulfate for treating adults with acute asthma in the emergency departmentLong-acting beta2-agonists for chronic obstructive pulmonary diseaseIntravenous magnesium sulfate for treating children with acute asthma in the emergency departmentLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisInhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseSafety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviewsIntravenous magnesium sulfate for treating adults with acute asthma in the emergency departmentCombination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and childrenHome telemonitoring and remote feedback between clinic visits for asthmaInterventions to improve inhaler technique for people with asthmaIncreased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and childrenAsthma education for school staffInterventions to improve adherence to inhaled steroids for asthmaAsthma education for school staffPsychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis.The Cost Effectiveness of Psychological and Pharmacological Interventions for Social Anxiety Disorder: A Model-Based Economic Analysis.Lay-led and peer support interventions for adolescents with asthma.Interventions to improve adherence to inhaled steroids for asthma.Interventions to improve inhaler technique for people with asthma.
P50
Q24185767-9959D255-3AAC-43AE-B46A-F2262D4AA8DBQ24185850-55CAD542-9FE6-45FC-A03D-378B4159C0FBQ24185891-1BB11F01-DEE1-440F-82B2-628014DAE155Q24186370-7E1B8A0C-5038-43E0-8914-30B29CD18D1DQ24186406-C43F9758-CD85-40E4-AED9-039279BB305BQ24186764-D73B752C-8547-452E-98F1-AE5C036AB1BBQ24187031-9AE06148-7D6B-4B44-889B-C0F2BA1E6C1DQ24187082-D5ABA429-4E78-4A20-862B-0B506A5899B4Q24187182-424A8515-51FC-412C-9C52-A3F82029A2C1Q24187322-0BD6BF41-1551-4F3D-9358-E78655530486Q24187595-BF39A65B-93B6-41BA-86F1-081935335D93Q24187736-00350110-0766-4EE6-AF82-7F874597242AQ24187757-7D4A9C3A-3918-4359-9F82-70D8F5954F35Q24187884-EF470ED4-FDC3-469A-8DB2-7DC3BFD638C0Q24188162-A97E6BAA-FFE8-44D4-BC10-60907EE87622Q24188163-46869560-90E0-4B3E-92DD-E7F8219C3206Q24188167-90D24CA3-4A1E-46B1-9AB4-CAADAC7A679BQ24188213-2C0EC843-FAA0-4743-8824-42BB326F5BD5Q24193977-7D4C4C80-D345-40BE-B58C-E0B5AC3C35BEQ24194037-55F21CED-A6FC-4172-B2CC-407F8C3B84AAQ24194130-75A36B15-E775-4C23-BC0D-05870D149B3CQ24194543-E7849000-E81B-459E-B1EE-2E32C519EFC3Q24197467-09CEB482-A9C3-41F3-8D7B-345BF22CC0F5Q24197583-FE03A1C6-9CF7-40BC-B93A-5E2707C594ACQ24197853-D72B5D71-ED9E-461A-8398-3F3469ECD6D9Q24197989-18406A91-D9AC-4232-8FF8-8A89BA1DD39BQ24200620-724D8803-3525-4AA8-8AC1-818FCF58CA31Q24201319-577D0B38-F81E-4A79-B281-3D2770C7E295Q24201774-3403F2DE-E7D4-4B44-966B-5602CE1D3576Q26470521-3532A0A7-D63A-4A70-892A-C4402B70F706Q26471255-C1F4B4AC-258C-4C3F-8989-27F3DCA26BDDQ26471520-884AABD4-6C63-45EF-A44C-FAA38F8BCDC1Q26471660-C3DE6A61-6143-4A59-83E6-E64AA3956E79Q26471748-61C67AA2-F42D-4B3A-AFB9-D6F56273E6E4Q29994604-7CCE0BD1-48AB-4E61-BBF0-414F14705ABBQ34879491-636880B4-3D9F-4E9C-A363-D4BCE5C24460Q35823225-C9665C31-CD32-441D-9635-AEBD6053ED74Q38728521-57FD29ED-4E1A-4BB2-9B0F-CF44C7BA70DCQ38729165-E18E6525-2442-4D76-B56E-D938E416C91CQ38911060-24A1F403-C929-45B2-9F6D-9BB4023AA7FC
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kayleigh Kew
@ast
Kayleigh Kew
@en
Kayleigh Kew
@es
Kayleigh Kew
@nl
type
label
Kayleigh Kew
@ast
Kayleigh Kew
@en
Kayleigh Kew
@es
Kayleigh Kew
@nl
prefLabel
Kayleigh Kew
@ast
Kayleigh Kew
@en
Kayleigh Kew
@es
Kayleigh Kew
@nl
P106
P31
P496
0000-0002-0623-6087